|
|
|
| Clinical observation of Lipoic Acid combined with Pancreatic Kininogenase Enteric-Coated Tablets in the treatment of type 2 diabetic peripheral neuropathy |
| ZHANG Ridong SHI Min |
| Department of Endocrinology, the Affiliated Huai′an No.1 People′s Hospital of Nanjing Medical University, Jiangsu Province, Huai′an 223300, China |
|
|
|
Abstract Objective To compare the therapeutic effect of Lipoic Acid and Lipoic Acid combined with Pancreatic Kininogenase Enteric-Coated Tablets (Yikai) on type 2 diabetic peripheral neuropathy. Methods From January 2018 to January 2019, 60 patients with diabetic peripheral neuropathy were hospitalized in the Department of Endocrinology, the Affiliated Huai′an No.1 People′s Hospital of Nanjing Medical University were enrolled. The patients were divided into the observation group and the control group by random number table method, with 30 patients in each group. The control group was given intravenous infusion of Lipoic Acid, and the observation group was given intravenous infusion of Lipoic Acid combined with Yikai oral administration for two weeks. The clinical efficacy was evaluated, electromyography, oxidative stress and inflammation indexes of the two groups before and after treatment were evaluated respectively. Results After treatment, the total effective rate of the observation group was higher than that of the control group (P ＜ 0.05). Sensory conduction velocity (SNCV) and motor conduction velocity (MNCV) of the common peroneal and median nerves in the two groups were not significantly different from those before treatment (P ＞ 0.05). After treatment, SNCV and MNCV of the common peroneal nerve and median nerve in both groups were higher than those before treatment, and SNCV and MNCV of the observation group were higher than those of the control group, with statistically significant differences (all P ＜ 0.05). Malondialdehyde (MDA), reactive oxygen species (ROS), advanced oxidizing protein products (AOPPs) and superoxide dismutase (SOD) in the two groups were not significantly different before treatment (P ＞ 0.05). After treatment, MDA, ROS and AOPPs in both groups were lower than those before treatment, SOD was higher than that before treatment, SOD in the observation group was higher than that in the control group, while MDA, ROS and AOPPs were lower than those in the control group, with statistically significant differences (all P ＜ 0.05). Comparison of hypersensitive C-reactive protein (hs-CPR), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) before treatment between the two groups showed no significant difference (P ＞ 0.05). After treatment, hs-CPR, IL-6 and TNF-α in the two groups were all lower than those before treatment, and hs-CPR, IL-6 and TNF-α in the observation group were lower than those in the control group, with statistically significant differences (all P ＜ 0.05). Conclusion Intravenous infusion of Lipoic Acid combined with Yikai oral administration can effectively improve the clinical symptoms of patients with type 2 diabetes peripheral neuropathy, which may be related to reducing oxidative stress and improving the state of micro-inflammation. It plays a good synergistic effect and is worthy of clinical promotion.
|
|
|
|
|
|
[1] Morishita Y，Hanawa S，Miki T，et al. The association of plasma prorenin level with all oxidative stress marker，8-OHdG，in nondiabetic hemodialysis patients [J]. Clin Exp Nephml，2011，15（3）：398-404.
[2] Alam U，Riley DR，Jugdey RS，et al. Diabetic Neuropathy and Gait：A Review [J]. Diabetes Ther，2017，8（6）：1253-1264.
[3] 中华医学会糖尿病学分会.中国2型糖尿病防治指南（2017年版）[J].中华糖尿病杂志，2018，10（1）：4-64.
[4] Pop-busui R，Boulton AJ，Feldman EL，et al. Diabeticneuropathy：a position statement by the american diabetes association [J]. Diabetes Care，2017，40（1）：136-154.
[5] Ziegler D，Papanas N，Vinik AI，et al. Epidemiology of polyneuropathy in diabetes and prediabetes [J]. Handb Clin Neurol，2014，12（6）：3-22.
[6] Jiang DQ，Xu LC，Jiang LL，et al. Fasudil combined with methylcobalamin or lipoic acid can improve the nerve conduction velocity in patients with diabetic peripheral neuropathy：A metaanalysis [J]. Medwine（Baltimore），2018， 97（27）：113-190.
[7] 李慧.治疗糖尿病相关疾病药物的临床试验研究进展[J].国际药学研究杂志，2017，44（7）：680-686.
[8] 张圆，袁慧娟，赵志刚.糖尿病神经病变研究进展[J].中华糖尿病杂志，2018，10（4）：295-299.
[9] Santos TRM，Melo JV，Leite NC，et al. Usefulness of the vibration perception thresholds measurement as a diagnostic method for diabetic peripheral neuropathy：Results from the Riode Janeiro type 2 diabetes cohort study [J]. J Diabetes Complications，2018，32（8）：770-776.
[10] 宗海军，唐梅.甲钴胺联合加巴喷丁或普瑞巴林治疗痛性糖尿病周围神经病变疗效的比较[J].中国糖尿病杂志，2014，22（3）：210-212.
[11] Feldman EL，Nave KA，Jensen TS，et al. New horizons in diabetic neuropathy：mechanisms，bioenergetics，and Pain [J]. Neuron，2017，93（6）：1296-1313.
[12] Limin W，Pei G，Mei Z，et al. Prevalence and Ethnic Pattern of Diabetes and Prediabetes in China in 2013 [J]. JAMA，2017，317（24）：2515-2523.
[13] Abbott CA，Malik RA，Van E，et al. Prevalence and characteristics of painful diabetic neurapathy in a large Community-Based Diabetic population in the UK [J]. Diabetes Care，2011，34（10）：2220-2224.
[14] Snedecor SJ，Sudharshan L，Cappellefi JC，et al. Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy [J]. Pain Pract，2013，14（2）：167-184.
[15] Sieberg CB，Taras C. Gomaa A，et al. Neuropathic pain drives anxiety behavior in mice，results consistent with anxiety levels in diabetic neuropathy patients [J]. Pain Rep，2018，3（3）：651-670.
[16] Dan Z. The sensory symptoms of diabetic polyneuropathy are improved with α-lipoic acid THD SYDNEY trial [J]. Diabetes Care，2009，26（2）：770-776.
[17] Petrova D，Stambolieba K. Effect of alpha-lipoie acid on the postural stability of patients with diabetic peripheral neuropathy [J]. J Neurol Sci，2013（Suppl 1）：441-442.
[18] 徐雁，邹建洲，刘中华，等.维持性血液透析患者外周血单个核细胞核因子κB活性与微炎症、氧化应激状况及心血管疾病的关系[J].肾脏病与透析肾移植杂志，2011， 20（6）：506-511.
[19] 孟庆胜，朱涛.糖尿病神经病变患者单核细胞TOLL样受体4的表达及其与血浆肿瘤坏死因子α、白介素6的相关性研究[J].中国糖尿病杂志，2017，25（2）：97-102.
[20] 焦洋，于洋，李波，等．氢气抑制核因子-κB通路对糖尿病周围神经病变的保护作用[J].中国现代神经疾病杂志，2013，13（9）：772-777. |
|
|
|
